HyBryte™ use in early-stage cutaneous T-cell lymphoma

• Main Authors: Brian Poligone (Author), Carolina V. Alexander-Savino (Author), Ellen J. Kim (Author), Aaron R. Mangold (Author), Jennifer Desimone (Author), Henry K. Wong (Author), Adam T. Rumage (Author), Oreola Donini (Author), Andrea Haulenbeek (Author), Christopher J. Schaber (Author), Richard Straube (Author), Christopher Pullion (Author), Alain H. Rook (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Cutaneous T-cell lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma of the skin, where at later stages skin-homing malignant T-cells affect lymph nodes, blood, and visceral organs. Even though early CTCL does not affect survival, it can progress to more advanced stages of disease and have a significant effect on the quality of life of patients. Although expectant management is a treatment consideration in early disease stages, most patients cycle through different skin-directed therapies throughout their lifetime. It can become a challenge to manage the serious and accumulating risk of side effects of these therapies, including various skin cancers and skin damage. Adverse effects from topical therapies limit their long-term utility. Thus, there is an unmet need for well-characterized therapies that have a rapid onset of action and minimal long-term/cumulative side effect profile. Most recently, the results of a Phase 3 study of topical HyBryte™ as a potential treatment for CTCL demonstrated its efficacy and safety profile. This article summarizes what is known about HyBryte™, focuses on its mechanism of action, and highlights its effectiveness, safety, and tolerability in the context of other current FDA-approved topical therapies for CTCL.

Item Description

2674-0338
10.3389/fddsv.2023.1298453